First Citizens Bank & Trust’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-1,478
Closed -$420K – 409
2022
Q1
$420K Sell
1,478
-178
-11% -$54.9K 0.02% 244
2021
Q4
$624K Buy
1,656
+18
+1% +$6.99K 0.02% 208
2021
Q3
$676K Buy
1,638
+193
+13% +$80.2K 0.03% 197
2021
Q2
$535K Buy
+1,445
New +$483K 0.03% 199
2017
Q1
– Sell
-4,210
Closed -$321K – 486
2016
Q4
$321K Sell
4,210
-1,839
-30% -$140K 0.04% 324
2016
Q3
$504K Buy
6,049
+30
+0.5% +$2.52K 0.05% 245
2016
Q2
$496K Buy
6,019
+356
+6% +$29.3K 0.04% 273
2016
Q1
$430K Buy
5,663
+2,849
+101% +$211K 0.04% 302
2015
Q4
$226K Buy
+2,814
New +$203K 0.02% 344
2015
Q3
– Sell
-2,860
Closed -$201K – 393
2015
Q2
$201K Buy
2,860
+182
+7% +$13.5K 0.01% 399
2015
Q1
$212K Buy
+2,678
New +$198K 0.01% 368
2013
Q4
– Sell
-4,609
Closed -$213K – 436
2013
Q3
$213K Buy
+4,609
New +$211K 0.01% 1017

Other funds holding CRL

First Citizens Bank & Trust's CRL Position: Q2 2022 in Review

First Citizens Bank & Trust sold out of Charles River Laboratories (CRL) in Q2 2022, closing a stake of 1,478 shares — an estimated $420K sold.

First Citizens Bank & Trust first reported a position in CRL in Q3 2013 and held it in 12 quarters. The position peaked at $676K in Q3 2021. 627 funds tracked by Wall St. Rank hold CRL as of Q2 2022.

  • First Citizens Bank & Trust reported no remaining Charles River Laboratories position as of Q2 2022 after selling out during the quarter.
  • First Citizens Bank & Trust sold 1,478 Charles River Laboratories shares in Q2 2022, an estimated $420K.
  • First Citizens Bank & Trust first reported a position in Charles River Laboratories in Q3 2013 and held it in 12 quarters.
  • First Citizens Bank & Trust's Charles River Laboratories position peaked at $676K in Q3 2021.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2022.

Based on First Citizens Bank & Trust's 13F filing for Q2 2022, filed 26 Jul 2022.